Identifying risk factors for refractory febrile neutropenia in patients with lung cancer

Masaki Fujita, Shoji Tokunaga, Satoshi Ikegame, Eiji Harada, Takemasa Matsumoto, Junji Uchino, Kentaro Watanabe, Yoichi Nakanishi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Information about the development of febrile neutropenia in patients with solid tumors remains insufficient. In this study, we tried to identify the risk factors for refractory febrile neutropenia in patients with lung cancer. A total of 59 neutropenic fever episodes associated with anti-tumor chemotherapy for lung cancer were retrospectively analyzed. We compared patient characteristics according to their initial response to treatment with antibiotics. For 34 of 59 (58%) episodes a response to initial antibiotics was obtained whereas 25 of 59 (42%) were refractory to treatment. Multivariate analysis demonstrated independent risk factors for refractory febrile neutropenia with lung cancer. These risk factors were the severity of febrile neutropenia (odds ratio (OR) 6.11; 95% confidence interval (CI) 1.85-20.14) and C-reactive protein more than 10 mg/dl (OR 4.39; 95% CI 1.22-15.74). These factors could predict outcome for patients with lung cancer who develop refractory febrile neutropenia.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalJournal of Infection and Chemotherapy
Volume18
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Febrile Neutropenia
Lung Neoplasms
Odds Ratio
Confidence Intervals
Anti-Bacterial Agents
C-Reactive Protein
Neoplasms
Fever
Multivariate Analysis
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Identifying risk factors for refractory febrile neutropenia in patients with lung cancer. / Fujita, Masaki; Tokunaga, Shoji; Ikegame, Satoshi; Harada, Eiji; Matsumoto, Takemasa; Uchino, Junji; Watanabe, Kentaro; Nakanishi, Yoichi.

In: Journal of Infection and Chemotherapy, Vol. 18, No. 1, 02.2012, p. 53-58.

Research output: Contribution to journalArticle

Fujita, M, Tokunaga, S, Ikegame, S, Harada, E, Matsumoto, T, Uchino, J, Watanabe, K & Nakanishi, Y 2012, 'Identifying risk factors for refractory febrile neutropenia in patients with lung cancer', Journal of Infection and Chemotherapy, vol. 18, no. 1, pp. 53-58. https://doi.org/10.1007/s10156-011-0283-5
Fujita, Masaki ; Tokunaga, Shoji ; Ikegame, Satoshi ; Harada, Eiji ; Matsumoto, Takemasa ; Uchino, Junji ; Watanabe, Kentaro ; Nakanishi, Yoichi. / Identifying risk factors for refractory febrile neutropenia in patients with lung cancer. In: Journal of Infection and Chemotherapy. 2012 ; Vol. 18, No. 1. pp. 53-58.
@article{4ceacbbaed3c4bb59861376fd49334fd,
title = "Identifying risk factors for refractory febrile neutropenia in patients with lung cancer",
abstract = "Information about the development of febrile neutropenia in patients with solid tumors remains insufficient. In this study, we tried to identify the risk factors for refractory febrile neutropenia in patients with lung cancer. A total of 59 neutropenic fever episodes associated with anti-tumor chemotherapy for lung cancer were retrospectively analyzed. We compared patient characteristics according to their initial response to treatment with antibiotics. For 34 of 59 (58{\%}) episodes a response to initial antibiotics was obtained whereas 25 of 59 (42{\%}) were refractory to treatment. Multivariate analysis demonstrated independent risk factors for refractory febrile neutropenia with lung cancer. These risk factors were the severity of febrile neutropenia (odds ratio (OR) 6.11; 95{\%} confidence interval (CI) 1.85-20.14) and C-reactive protein more than 10 mg/dl (OR 4.39; 95{\%} CI 1.22-15.74). These factors could predict outcome for patients with lung cancer who develop refractory febrile neutropenia.",
author = "Masaki Fujita and Shoji Tokunaga and Satoshi Ikegame and Eiji Harada and Takemasa Matsumoto and Junji Uchino and Kentaro Watanabe and Yoichi Nakanishi",
year = "2012",
month = "2",
doi = "10.1007/s10156-011-0283-5",
language = "English",
volume = "18",
pages = "53--58",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Identifying risk factors for refractory febrile neutropenia in patients with lung cancer

AU - Fujita, Masaki

AU - Tokunaga, Shoji

AU - Ikegame, Satoshi

AU - Harada, Eiji

AU - Matsumoto, Takemasa

AU - Uchino, Junji

AU - Watanabe, Kentaro

AU - Nakanishi, Yoichi

PY - 2012/2

Y1 - 2012/2

N2 - Information about the development of febrile neutropenia in patients with solid tumors remains insufficient. In this study, we tried to identify the risk factors for refractory febrile neutropenia in patients with lung cancer. A total of 59 neutropenic fever episodes associated with anti-tumor chemotherapy for lung cancer were retrospectively analyzed. We compared patient characteristics according to their initial response to treatment with antibiotics. For 34 of 59 (58%) episodes a response to initial antibiotics was obtained whereas 25 of 59 (42%) were refractory to treatment. Multivariate analysis demonstrated independent risk factors for refractory febrile neutropenia with lung cancer. These risk factors were the severity of febrile neutropenia (odds ratio (OR) 6.11; 95% confidence interval (CI) 1.85-20.14) and C-reactive protein more than 10 mg/dl (OR 4.39; 95% CI 1.22-15.74). These factors could predict outcome for patients with lung cancer who develop refractory febrile neutropenia.

AB - Information about the development of febrile neutropenia in patients with solid tumors remains insufficient. In this study, we tried to identify the risk factors for refractory febrile neutropenia in patients with lung cancer. A total of 59 neutropenic fever episodes associated with anti-tumor chemotherapy for lung cancer were retrospectively analyzed. We compared patient characteristics according to their initial response to treatment with antibiotics. For 34 of 59 (58%) episodes a response to initial antibiotics was obtained whereas 25 of 59 (42%) were refractory to treatment. Multivariate analysis demonstrated independent risk factors for refractory febrile neutropenia with lung cancer. These risk factors were the severity of febrile neutropenia (odds ratio (OR) 6.11; 95% confidence interval (CI) 1.85-20.14) and C-reactive protein more than 10 mg/dl (OR 4.39; 95% CI 1.22-15.74). These factors could predict outcome for patients with lung cancer who develop refractory febrile neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=84862135207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862135207&partnerID=8YFLogxK

U2 - 10.1007/s10156-011-0283-5

DO - 10.1007/s10156-011-0283-5

M3 - Article

C2 - 21773751

AN - SCOPUS:84862135207

VL - 18

SP - 53

EP - 58

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 1

ER -